Edition:
United States

Gemphire Therapeutics Inc (GEMP.OQ)

GEMP.OQ on NASDAQ Stock Exchange Global Market

5.87USD
20 Apr 2018
Change (% chg)

$-0.06 (-1.01%)
Prev Close
$5.93
Open
$5.82
Day's High
$5.93
Day's Low
$5.81
Volume
5,942
Avg. Vol
31,371
52-wk High
$21.59
52-wk Low
$5.55

Chart for

About

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to... (more)

Overall

Beta: --
Market Cap(Mil.): $80.73
Shares Outstanding(Mil.): 13.78
Dividend: --
Yield (%): --

Financials

  GEMP.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -3.23 -- --
ROI: -200.93 -0.74 13.19
ROE: -271.97 -2.80 15.00

BRIEF-Gemphire Therapeutics Reports Qtrly Loss Per Share $0.63‍​

* GEMPHIRE THERAPEUTICS REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS

Mar 15 2018

BRIEF-Gemphire Therapeutics reports qtrly loss of $0.82‍​/shr

* Gemphire Therapeutics Inc qtrly loss per share $0.82‍​ Source: (http://bit.ly/2iaJuNF) Further company coverage:

Nov 13 2017

Earnings vs. Estimates